Volume 96 Issue 1 | p. 13 | Concentrates
Issue Date: January 1, 2018

Aptinyx raises funds for neurologic drugs

Department: Business
Keywords: Neuroscience, Aptinyx, N-methyl-D-aspartate

Aptinyx has completed a $70 million series B fundraising intended to advance its pipeline of drugs that treat neurologic disorders by modulating N-methyl-d-aspartate receptors. One of those compounds, NYX-2925, is in Phase II clinical trials involving people with diabetes-related pain. Aptinyx was formed in 2015 when Allergan spun off the drug discovery operations of Naurex, a company it acquired.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment